Authors
Latest:
A Closer Look at PBM Spread PricingWhile often portrayed in a negative light, it is important to find a balanced perspective on its role in the pharma sector.
Latest:
The Risk of Doubling Down on PharmaExamining the divestment risks, as more large companies look to spin off consumer health and other business units to focus on branded pharmaceuticals
Latest:
Navigating New State Drug Price Transparency LawsAs the State Drug Pricing Transparency Program expands, what does that mean for manufacturers? Jesse Mendelsohn, Vice President, Centers of Excellence for Model N, the leader in cloud revenue management solutions for life science companies, discusses challenges for manufacturers as the State Price Transparency Program expands how they should plan for this change and the solutions they will need.
Latest:
Keep Supply Chains Flowing with Streamlined Healthcare Vendor PaymentsVendor relationships are best supported by practices that emphasize efficiency, visibility, and the streamlining of the invoice to pay process
Latest:
Transforming Pharma Supply Chains for the Age of Personalized CareA prediction of how this shift toward patient-centric care may look.
Latest:
How Efficient Cold Chain Logistics Can Change the Lives of Rare Disease PatientsIf manufacturers cannot ensure safe, cost-effective delivery of treatments for rare diseases, access will remain a challenges for many patients living with these conditions.
Latest:
Algorithms and accountabilityDrug shortages are inevitable—being caught off guard isn’t. The best ways distributors can use and position data to drive today’s inventory solutions
Latest:
Getting the Lay of the Land After a Banner Year for BiosimilarsBiosimilars market experiences massive growth, but regulatory and adoption challenges remain.
Latest:
Adalimumab Biosimilar Now Available at Significant Discount to HumiraBoehringer Ingelheim’s unbranded adalimumab-adbm biosimilar will be available at an 81% discount to adalimumab (Humira).
Latest:
Building Adaptability in the Pharmaceutical IndustryWhy having these strategies for results—amid disruptions—will be critical to success.
Latest:
Why M&A is back; AI regulations lacking; quantum sensing investment, and more: Pharma Pulse for February 23, 2024The latest news for pharma industry insiders.
Latest:
Challenges and Benefits of Implementing IDMP in the Pharmaceutical IndustryThe Identification of Medicinal Product framework seeks to establish a common language for identifying, documenting, and exchanging information about medicinal products.
Latest:
Reimagining Closed-Loop Marketing Strategies for Pharma CompaniesThe pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Latest:
Closing a Key Gap in DSCSA ComplianceOutlining the work of the Open Credentialing Initiative in establishing digital proof of identity, licensure status, and authorship using digital wallets and verifiable credentials
Latest:
Forecasting the 2025 Healthcare Logistics SpaceHow will supply chains in the space continue to develop?
Latest:
What the Pharma Industry Can Learn from the Food Sector about Digital Quality ManagementPharma compliance requires stringent quality assurance in order to ensure patient safety, but the default for many pharma companies is still to use manual processes for supplier vetting and reporting. Gaëlle Jaron looks at how the food industry might inspire pharma to transform its processes
Latest:
Environmental Sustainability: An Imperative for the Life Sciences SectorGiven the biopharma sector‘s complex set of networks and supply chains, so it is not straightforward to shift towards net zero across all operations.
Latest:
Why AI Advances in CGT Require Getting Data RightAddressing the bottlenecks in cell and gene therapy manufacturing through a well-designed artificial intelligence approach is essential to avoiding data siloes.
Latest:
3PLs and New VoicesOur February issue is highlighted by an examination of the latest trends and strategies from the perspective of third-party logistics providers, and introduces new expert commentary covering a pair of pivotal realms in the pharma supply chain journey.
Latest:
Assessing Adoption of Hybrid DtP ModelsThe benefits of hybrid direct-to-patient studies and supply chain structures in boosting drug access, influencing clinical trial design
Latest:
Exploring Uses of RFID TechnologyOffer potential to improve patient care, including in medication adherence.
Latest:
DSCSA Beyond the November Deadline: Operationalize Compliance in the WarehouseCompliance with the Drug Supply Chain Security Act (DSCSA) is crucial to ensure a secure and efficient pharmaceutical supply chain. Industry experts share strategies for implementing serialized data tracking, overcoming compliance challenges, and fostering collaboration across the supply chain to maintain operational efficiency and patient safety.
Latest:
Rethinking Pharma Commercialization Models as Healthcare EvolvesHow cross-functional commercialization teams can hone their role within clinical management pathways, communicate value to all stakeholders, achieve excellence in evidence generation, and maximize the opportunities of digital technologies
Latest:
Precision-based DiagnosticsPrecision-based diagnostic approaches can help us improve patient outcomes and reach patient success sooner
Latest:
A First-Class Patient Engagement Service: Do Strategic Partnerships Hold the Key?Delivering a first-class patient engagement approach is complex enough in a large pharma market. For smaller European markets, it can be even more challenging. Ian Riches looks at how pharma companies can put all patients at the center of their engagement plans, no matter which country they live in.
